Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20336491 | 0.91 | ALDH1A1 (0.33) | ALDH1A1KDM4EDPP4 | |
| SCHEMBL4508273 | 0.85 | CA14 (0.36) | ALDH1A1 | |
| SCHEMBL23795394 | 0.76 | DUT (0.31) | DUT | |
| SCHEMBL17363339 | 0.76 | CA14 (0.33) | ALDH1A1DPP4 | |
| SCHEMBL2880215 | 0.75 | DUT (0.35) | ALDH1A1KDM4EDUT | |
| SCHEMBL2880342 | 0.74 | DUT (0.35) | DUT | |
| SCHEMBL2516385 | 0.74 | DUT (0.35) | DUT | |
| SCHEMBL3756533 | 0.72 | DUT (0.35) | DUT | |
| SCHEMBL2044848 | 0.72 | ALDH1A1 (0.50) | ALDH1A1KDM4EDPP4 | |
| SCHEMBL20661642 | 0.71 | TSHR (0.53) | ALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185512-A1 | NANOPARTICLES FOR DRUG DELIVERY | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| WO-2014124329-A1 | NANOPARTICLES FOR DRUG DELIVERY | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| EP-1633717-B1 | P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| US-7408065-B2 | P2X7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1633717-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004106305-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | ALDH1A1 985/4885KDM4E 1175/4885DUT 1485/4885 |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | P2RX7, P2RX1, P2RX2 | ALDH1A1 1580/4885KDM4E 3521/4885DUT 2520/4885 |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | P2RX7, P2RX1, P2RX2 | ALDH1A1 1580/4885KDM4E 3521/4885DUT 2520/4885 |
| US-20180185512-A1 | NANOPARTICLES FOR DRUG DELIVERY | NCL, NPC1, SNX9 | ALDH1A1 1563/4885KDM4E 3749/4885DUT 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.